A Randomized, Double-masked, Sham-controlled Study to Evaluate the Efficacy of Peri-operative Farcimab in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

In this phase IV, randomized, double-masked, sham-controlled study the investigators hope to determine the efficacy in peri-operative faricimab (Vabysmo) compared to sham in limiting complications from pars plana vitrectomy for diabetic vitreous hemorrhage with or without tractional retinal detachments.

Start Date01 Aug 2024

Sponsor / Collaborator

University of Colorado Denver

NCT06439576 / RecruitingNot Applicable

China Faricimab Real World Evidence: Evaluation of Faricimab Effectiveness, Safety and Treatment Pattern, in Diabetic Macular Edema, Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration: The Farseeing Study

The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in China. It is a primary data collection, non-interventional, prospective and retrospective, multi-center study designed to collect real-world, long-term data to gain clinical evidence on faricimab, by observing cohorts of patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) who are receiving treatment with faricimab.

Start Date09 May 2024

Sponsor / Collaborator

Shanghai Roche Pharmaceuticals Ltd.

NCT06271330 / Not yet recruitingNot ApplicableIIT

A Multicenter Real-life Observational Retrospective Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With Refractory or Dependent Exudative AMD

Age-related macular degeneration (AMD) is a degenerative retinal disease. The prognosis of the exudative form was transformed by the introduction of the anti-VEGF monoclonal antibody treatments ranibizumab [1] and aflibercept [2] in the 2010s. In 2022, a new molecule, Faricimab, proved its efficacy in exudative AMD. It is a bi-specific monoclonal antibody against VEGF-A and ANG2. The drug has been granted marketing authorization in France, with reimbursement due to begin in October 2023 for naïve patients as well as for those already treated with ranibizumab or aflibercept. The main advantage of this compound [3] is that it extends the injection interval in the Treat and Extend (T&E) protocol, which is more extensive than with previous anti-VEGF agents.
The patients included in the faricimab Phase III study were all naïve to any anti-VEGF treatment. In practice, faricimab is likely to offer hope to patients already treated with anti-VEGF with a short injection interval to lengthen the number of weeks between injections.
As the treatment will be on sale in pharmacies from October 2023, a switch study from previous anti-VEGF drugs to faricimab would contribute to an initial real-life evaluation of the drug in this indication.

Start Date01 Apr 2024

Sponsor / Collaborator

Nantes University Hospital

[+1]

100 Clinical Results associated with Faricimab

100 Translational Medicine associated with Faricimab

100 Patents (Medical) associated with Faricimab

127

Literatures (Medical) associated with Faricimab

01 Mar 2024·American journal of ophthalmology case reports

Two cases of diabetic macular edema with diminished areas of retinal non-perfusion and microaneurysms after intravitreal faricimab injections

Author: Nakagawa, Norihiko ; Shunto, Takuya ; Nishiyama, Issei ; Sawa, Miki

Purpose:

To report two cases of diabetic macular edema (DME) treated with intravitreal faricimab injections (IVFs), including the assessment of retinal microaneurysms and extent of retinal capillary non-perfusion using fluorescein angiography (FA) and indocyanine green angiography (IA).

Observations:

Case 1: A 72-year-old man presented with aflibercept-resistant DME in the left eye, with a best-corrected visual acuity (BCVA) of 20/16. FA showed areas of retinal capillary non-perfusion and focal leakage in the macular area of the left eye. IA revealed numerous microaneurysms in the temporal region of the macula. Four consecutive monthly IVFs were administered to the left eye, and DME eventually diminished. After the loading phase, the BCVA was maintained at 20/16 with reduced visual distortion. FA showed improvement of macular leakage and stable retinal capillary non-perfusion areas, and the foveal avascular zone was clearly observed. The disappearance of numerous microaneurysms was confirmed on IA images.Case 2: An 80-year-old woman developed DME with macular vein occlusion in the left eye after panretinal laser photocoagulation for proliferative diabetic retinopathy. The patient's BCVA was 20/32. DME was resistant to subtenon triamcinolone injections. FA revealed focal areas of retinal capillary non-perfusion and persistent leakage in the macular area of the left eye. IA revealed scattered microaneurysms within the retinal arcade. Four consecutive monthly IVFs were administered to the left eye, and DME eventually diminished. After the loading phase, the BCVA was maintained at 20/32. FA showed improvement of macular leakage and stable retinal capillary non-perfusion areas. The reduction of microaneurysms was confirmed on IA images.

Conclusions and importance:

These case reports highlight the potential of faricimab as an alternative anti-vascular endothelial growth factor drug for treatment-resistant DME, including reduction of retinal microaneurysms and stabilization of the areas of retinal capillary non-perfusion. However, continuation of a robust treatment regimen may be required to achieve these objectives.

01 Mar 2024·Ophthalmology science

Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration

Article

Author: Dai, Jian ; Neubert, Ales ; Kawczynski, Michael G ; Anegondi, Neha ; Kikuchi, Yusuke ; Quezada-Ruiz, Carlos ; Ferrara, Daniela

Purpose:

To develop machine learning (ML) models to predict, at baseline, treatment outcomes at month 9 in patients with neovascular age-related macular degeneration (nAMD) receiving faricimab.

Design:

Retrospective proof of concept study.

Participants:

Patients enrolled in the phase II AVENUE trial (NCT02484690) of faricimab in nAMD.

Methods:

Baseline characteristics and spectral domain-OCT (SD-OCT) image data from 185 faricimab-treated eyes were split into 80% training and 20% test sets at the patient level. Input variables were baseline age, sex, best-corrected visual acuity (BCVA), central subfield thickness (CST), low luminance deficit, treatment arm, and SD-OCT images. A regression problem (BCVA) and a binary classification problem (reduction of CST by 35%) were considered. Overall, 10 models were developed and tested for each problem. Benchmark classical ML models (linear, random forest, extreme gradient boosting) were trained on baseline characteristics; benchmark deep neural networks (DNNs) were trained on baseline SD-OCT B-scans. Baseline characteristics and SD-OCT data were merged using 2 approaches: model stacking (using DNN prediction as an input feature for classical ML models) and model averaging (which averaged predictions from the DNN using SD-OCT volume and from classical ML models using baseline characteristics).

Main Outcome Measures:

Treatment outcomes were defined by 2 target variables: functional (BCVA letter score) and anatomical (percent decrease in CST from baseline) outcomes at month 9.

Results:

The best-performing BCVA regression model with respect to the test coefficient of determination (R²) was the linear model in the model-stacking approach with R² of 0.31. The best-performing CST classification model with respect to test area under receiver operating characteristics (AUROC) was the benchmark linear model with AUROC of 0.87. A post hoc analysis showed the baseline BCVA and the baseline CST had the most effect in the all-model prediction for BCVA regression and CST classification, respectively.

Conclusions:

Promising signals for predicting treatment outcomes from baseline characteristics were detected; however, the predictive benefit of baseline images was unclear in this proof-of-concept study. Further testing and validation with larger, independent datasets is required to fully explore the predictive capacity of ML models using baseline imaging data.

Financial Disclosures:

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

01 Feb 2024·Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration

Article

Author: Maruyama-Inoue, Maiko ; Inoue, Tatsuya ; Kadonosono, Kazuaki ; Yanagi, Yasuo

Abstract:

Purpose:

This study aimed to compare functional and morphologic changes in the loading phase between patients with treatment-naïve macular neovascularization (MNV) due to neovascular age–related macular degeneration (nAMD) treated with either intravitreal brolucizumab (IVBr) or intravitreal faricimab (IVF) injections in a clinical setting.

Methods:

We retrospectively studied 92 consecutive eyes of 90 patients with neovascular nAMD who were scheduled to receive IVBr (42 eyes of 41 patients) or IVF (50 eyes of 49 patients) injections between October 2021 and December 2022. All patients received three consecutive monthly injections of 6.0 mg/0.05 mL brolucizumab or 6.0 mg/0.05 mL faricimab. The best-corrected visual acuity (BCVA), central foveal thickness (CFT), and central choroidal thickness (CCT) at baseline and 1, 2, and 4 months after the initial treatment were measured and compared between the groups.

Results:

Thirty-seven eyes in IVBr group and forty-seven eyes in IVF group who finished treatments in the loading phase were assessed at the follow-up examination. The BCVA, CFT, and CCT changed significantly after loading phase in both groups (P < 0.05 for both comparisons). The IVBr group had more rapid improvement of the BCVA (P = 0.037) at 1 month than the IVF group, but there was no difference at 4 months (P = 0.367). The CFT and CCT decreases tended to be greater in the IVBr group than in the IVF group throughout the follow-up period. Of the five eyes excluded from the IVBr group, one eye (2.4%) each had intraocular inflammation (IOI) and was a non-responder, and two eyes (4.8%) had retinal pigment epithelial tears after treatment. Of the three eyes excluded from the IVF group, two eyes (4.0%) did not respond to the treatment.

Conclusions:

Both IVBr and IVF injections were well-tolerated and improved the VA in treatment-naïve patients with MNV due to nAMD after a loading phase, although IVBr caused a trend toward faster visual improvements in the BCVA. The IVBr group also had greater reductions of the CFT and CCT than the IVF group. However, the potential for adverse events and no response to treatment with each drug are considerations.

163

News (Medical) associated with Faricimab

20 Jun 2024

·www.globenewswire.com

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about July 15, 2024, to respective holders of record at the close of business on July 3, 2024. About XOMA CorporationXOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow the Company on LinkedIn. Forward-Looking Statements/Explanatory NotesCertain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify such forward-looking statements by terminology such as “will” or “shall”, the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; and if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-Q and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor contact:Juliane SnowdenXOMA+1-646-438-9754juliane.snowden@xoma.com Media contact:Kathy VincentKV Consulting & Management+1-310-403-8951kathy@kathyvincent.com

20 Jun 2024

·www.biospace.com

XOMA Declares Quarterly Preferred Stock Dividends - June 20, 2024

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about July 15, 2024, to respective holders of record at the close of business on July 3, 2024. About XOMA Corporation XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit or follow the Company on LinkedIn. Forward-Looking Statements/Explanatory Notes Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify such forward-looking statements by terminology such as “will” or “shall”, the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; and if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-Q and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor contact: Juliane Snowden XOMA +1-646-438-9754 juliane.snowden@xoma.com Media contact: Kathy Vincent KV Consulting & Management +1-310-403-8951 kathy@kathyvincent.com

29 May 2024

·firstwordpharma.com

Merck & Co. revives ophthalmology efforts with $3B EyeBio takeout

Merck & Co. has reached a definitive agreement to buy ophthalmic drugmaker Eyebiotech as it looks to move back in the growing eye-disease therapies market. Speculation that a buyout was imminent was reported Tuesday evening by The Wall Street Journal, citing unnamed sources familiar with the situation.In the deal announced Wednesday, Merck said it would acquire all outstanding EyeBio shares for up to $3 billion, including an upfront payment of $1.3 billion in cash plus up to an additional $1.7 billion in developmental, regulatory and commercial milestone payments. The transaction is expected to close in the third quarter.The privately-held biotech, which operates in the US and UK, extended its Series A financing last November to a total of $130 million to boost its clinical development programme for retinal therapies. "The EyeBio team, under the leadership of David Guyer and Tony Adamis, has a strong track record of developing ground-breaking ophthalmology therapies," stated Dean Li, president of Merck Research Laboratories. "By combining our strengths, we aim to advance with rigour and speed the development of their promising pipeline of candidates targeting retinal diseases."Tri-specific antibody for AMD, DMEEyeBio’s lead asset is restoret (EYE103) — an intravitreally delivered, tri-specific antibody, which demonstrated positive visual and anatomic outcomes in the Phase Ib/IIa AMARONE study of patients with neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). Based on those results, restoret is expected to move into a pivotal Phase IIb/III trial of patients with DME in the second half of 2024.Guyer, who also founded Iveric Bio, which was bought out by Astellas for $5.9 billion last year, mentioned that EyeBio has another treatment in early development that could be complementary to restoret. He and Adamis plan to stay with EyeBio to continue developing the candidate.Merck exited the ophthalmology segment a decade ago to prioritise key areas such as oncology, immunology and vaccines. However, the drugmaker has recently been chasing deals to reduce dependence on its top-selling immunotherapy drug Keytruda (pembrolizumab), which is set to lose its main patent in 2028. Bayer and Regeneron Pharmaceuticals' Eylea (aflibercept), with $5.9 billion in sales last year, and Roche's Vabysmo (faricimab-svoa), which reached $2.7 billion in sales in 2023, are already used to treat wet AMD.

AcquisitionImmunotherapyClinical Result

100 Deals associated with Faricimab

External Link

KEGG	Wiki	ATC	Drug Bank
D11516	-	-	DB15303

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Retinal Vein Occlusion	JP	Chugai Pharmaceutical Co., Ltd.	26 Mar 2024
Retinal vein occlusion-related macular edema	US	Genentech, Inc.	26 Oct 2023
Age Related Macular Degeneration	JP	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Choroidal Neovascularization	JP	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Dystrophy, Macular	JP	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Diabetic macular oedema	US	Genentech, Inc.	28 Jan 2022
Wet age-related macular degeneration	US	Genentech, Inc.	28 Jan 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myopia, Degenerative	Phase 3	CN	Hoffmann-La Roche Ltd.	06 Mar 2024
Myopia, Degenerative	Phase 3	AU	Hoffmann-La Roche Ltd.	06 Mar 2024
Myopia, Degenerative	Phase 3	FR	Hoffmann-La Roche Ltd.	06 Mar 2024
Myopia, Degenerative	Phase 3	DE	Hoffmann-La Roche Ltd.	06 Mar 2024
Myopia, Degenerative	Phase 3	HK	Hoffmann-La Roche Ltd.	06 Mar 2024
Myopia, Degenerative	Phase 3	IT	Hoffmann-La Roche Ltd.	06 Mar 2024
Myopia, Degenerative	Phase 3	PL	Hoffmann-La Roche Ltd.	06 Mar 2024
Myopia, Degenerative	Phase 3	SG	Hoffmann-La Roche Ltd.	06 Mar 2024
Myopia, Degenerative	Phase 3	KR	Hoffmann-La Roche Ltd.	06 Mar 2024
Myopia, Degenerative	Phase 3	ES	Hoffmann-La Roche Ltd.	06 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04740905 (BALATON, GlobeNewswire) Manual	Phase 3	Retinal Vein Occlusion First line	553	Vabysmo	bnapafkozw(weawwnlohf) = krigcpavrn fqdclqlses (colsiadlva ) View more	Positive	01 Feb 2024
				aflibercept+Vabysmo (switched from aflibercept to Vabysmo)	bnapafkozw(weawwnlohf) = pzsxjnksyh fqdclqlses (colsiadlva ) View more
NCT04740931 (COMINO, GlobeNewswire) Manual	Phase 3	Retinal Vein Occlusion First line	729	Vabysmo	nmqztvkhwu(hwwakaslry) = pmfwmdlexb gstcwqwpvt (giooegsiex ) View more	Positive	01 Feb 2024
				aflibercept+ Vabysmo (switched from aflibercept to Vabysmo)	nmqztvkhwu(hwwakaslry) = ivlizwmqzx gstcwqwpvt (giooegsiex ) View more
NCT04740931 (BALATON and COMINO, Pubmed)	Phase 3	Retinal vein occlusion-related macular edema	-	Faricimab 6.0 mg	ohhhxlykhi(bkztztpbpm) = bdjzewkmqq zqkwptkuzy (wapwdlqwue ) View more	Positive	25 Jan 2024
				Aflibercept 2.0 mg	ohhhxlykhi(bkztztpbpm) = llvnwjeheo zqkwptkuzy (wapwdlqwue ) View more
NCT03622593 (YOSEMITE and RHINE, Pubmed)	Phase 3	Diabetic macular oedema	-	Faricimab 6.0 mg every 8 weeks	yuuffojwjv(pesmdjxiyb) = wqbmuekkfi dwwsecjzlr (axtaqfberu ) View more	-	01 Dec 2023
				Faricimab 6.0 mg T&E	yuuffojwjv(pesmdjxiyb) = pyvpgcdwzc dwwsecjzlr (axtaqfberu ) View more
NCT04597918 (CTgov)	Phase 2	Diabetic macular oedema	99	Faricimab	ggdmocjfdp(vywtrbazsy) = oydmjntsum mjrnmmofnq (ljrwwidomt, nbqmozduoq - sktgyylwdc) View more	-	01 Dec 2023
NCT04740931 \| NCT04740905 (COMINO, FDA) Manual	Phase 3	Retinal vein occlusion-related macular edema First line	1,282	VABYSMO (BALATON)	tuilhqrllc(aoqpsufqah) = jlkovadlxh skgaaycohr (ttlijifrxt, 15.7 - 18.1)	Non-inferior	26 Oct 2023
				Aflibercept (BALATON)	tuilhqrllc(aoqpsufqah) = lvhyeaterv skgaaycohr (ttlijifrxt, 16.3 - 18.6)
NCT05569148 (CTgov)	Phase 3	Wet age-related macular degeneration \| Diabetic macular oedema	35	Faricimab PFS Configuration	btgtdhgztc(dxqxrsmedv) = prtlgvrvbh gwhnzongqu (pihxzlgopa, zeadblgccx - ibmvpjakol) View more	-	10 Oct 2023
NCT03823287 \| NCT03823300 (TENAYA, LUCERNE, Pubmed)	Not Applicable	Age Related Macular Degeneration	120	Faricimab 6.0 mg	itchmzmoml(udcyqrszjp) = dxxsimgzlt sminvgoljc (wlkwxetbnx, 4.3 - 9.8) View more	-	09 Jun 2023
				Aflibercept 2.0 mg	itchmzmoml(udcyqrszjp) = fxhumpdcfq sminvgoljc (wlkwxetbnx, 4.4 - 10.0) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis